Clinigen Group (OTCMKTS:CLIGF) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research cut shares of Clinigen Group (OTCMKTS:CLIGF) from a hold rating to a sell rating in a research note issued to investors on Monday morning, Zacks.com reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of CLIGF stock opened at $12.90 on Monday. The stock’s 50 day simple moving average is $12.90. Clinigen Group has a 1-year low of $9.87 and a 1-year high of $12.90.



Featured Story: What is a Special Dividend?

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.